封面
市場調查報告書
商品編碼
1179953

2023-2030 年全球 DNA 檢測市場

Global DNA Testing Market - 2023-2030

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2023-2030),全球 DNA 檢測市場規模預計將以 7.4% 的複合年增長率增長。

DNA 測試,通常稱為基因測試,是一種醫學測試,可以檢測人類基因、染色體或蛋白質的變化。 這些突變可以揭示一個人是否患有遺傳病。 DNA 測試還可以確定您感染某些疾病或遺傳遺傳問題的風險。 DNA 測試是可選的。 是否接受測試是一個複雜的個人問題,因為測試有其優點、缺點和風險。 遺傳學家或遺傳諮詢師可以通過概述測試的優缺點並檢查其社會和情感影響來提供幫助。

市場動態

推動全球 DNA 檢測市場發展的主要因素是新檢測方法的開發和技術突破、直接面向消費者的 DNA 檢測需求不斷增長以及遺傳病和慢性病發病率的增加。這是主要因素推動全球測試市場。

新測試的開發和技術突破有望推動市場增長。

如今,加速的技術發展為市場增長開闢了廣泛的機會。 它正在推動專業治療領域檢測試劑盒市場的增長和慢性病市場的快速擴張。 一些國家的政府通過更加重視基因檢測的監管和提高公眾意識,成功地加速了全球對基因檢測的接受。 不斷增加的研發資金和主要參與者的大量市場佔有率為新進入者創造了很高的進入壁壘。 產品設計創新、改進的質量標準和強大的分銷合作夥伴關係是保持市場競爭力所必需的。

例如,2022年7月,Apollo高度專業化的高性能NGS檢測,如遺傳性癌症基因篩查(GCC)和藥物遺傳學篩查(PGx),將被引入到更廣泛的臨床領域將其推向市場,行業領先的軟件公司 1health.io Inc (1health) 已與 Apollo Health Group 合作。 1health 幫助診斷實驗室在臨床和直接面向消費者的市場中快速、安全地擴展測試。

2022 年 11 月 29 日,佩奇大學 (UP) 與華大基因決定在匈牙利開設聯合實驗室。 這是大學與華大基因母公司華大集團之間的合作協議中規定的。

高成本預計會阻礙市場增長。

實驗設備需要定期維護,成本高,是阻礙市場拓展的因素之一。

COVID-19 影響分析

COVID-19 也對市場產生了負面影響。 例如,在世衛組織將 COVID-19 指定為大流行病後,全球封鎖和社會疏遠對 DNA 檢測市場產生了負面影響。 這是因為遺傳諮詢師通常無法與患者一對一會面,醫生通常無法提供諮詢服務,實驗室也無法提供必要的檢測。 遺傳諮詢師不被視為醫療服務中心等組織的衛生專業人員。 因此,他們在封鎖期間不會免除醫療。 此外,診所限制了現場遺傳諮詢以幫助控制疾病。

但是,提供基因檢測的公司(例如 GeneDx)會根據臨床醫生的要求提供基因檢測選項。 正如醫院和其他醫療機構正在使用遠程醫療提供遺傳諮詢一樣,診所也開始這樣做。 此外,由於其重要性,父母測試仍然是影響最小的 DNA 測試方法。

因此,COVID-19 對基因檢測市場產生了重大影響。 然而,全球對基因檢測的需求現在已經接近疫情前的水平,而且這種需求預計還會繼續增長。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

  • 市場影響因素
    • 司機
      • 新測試的開發和技術突破
      • 直接面向消費者的 DNA 檢測需求不斷擴大
    • 約束因素
      • 高成本預計會阻礙市場增長。
    • 機會
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 樂器
  • 試劑
  • 軟件與服務

第8章技術

  • 聚合□鏈反應
  • 原位雜交
  • 音序器技術
  • 質譜
  • 其他

第 9 章按應用

  • 腫瘤學
  • 傳染病檢測
  • 肌源性疾病診斷
  • 臨床診斷確認
  • 產前診斷
  • 植入前診斷
  • 其他

第 10 章最終用戶

  • 護理點
  • 診斷中心
  • 自測/OTC

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • Natera, Inc.
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Roche Diagnostics
  • Abbott Laboratories
  • Cephide Inc
  • Gen-probe Inc
  • Illumina, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Hologic Inc
  • Siemens Healthier.

第14章 全球 DNA 檢測市場-DataM

簡介目錄
Product Code: DMCD1818

Market Overview

The global DNA testing market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 7.4% during the forecast period (2023-2030).

A DNA test, often known as genetic testing, is a medical examination that can spot changes in human genes, chromosomes, or proteins. These mutations can reveal if a person has a genetic disorder or not. DNA tests can also determine a person's risk of contracting a certain illness or passing along a genetic problem. Testing for DNA is optional. Whether to be tested is complex and personal because there are advantages to testing and drawbacks and risks. A geneticist or genetic counselor can assist by outlining the advantages and disadvantages of the test and by going over its social and emotional implications.

Market Dynamics

The major factors driving the global DNA testing market are the development of new tests and technological breakthroughs, demand for direct-to-consumer DNA testing is expanding. and the growing frequency of genetic and chronic diseases is the primary driver propelling the global market for genetic testing.

The development of new tests and technological breakthroughs is expected to drive the market's growth.

The current acceleration of technical development has opened up a wide range of opportunities for market growth. The increase helps the market for specialist testing kits for specialized treatment sectors and the rapid market expansion of chronic diseases. Governments in several countries have successfully accelerated the global acceptance of genetic testing by putting more emphasis on regulating it and increasing public awareness of it. A high entry barrier for new entrants has been created by the increased R&D funding and the large market presence of major enterprises. Innovation in product design, higher quality standards, and strong distribution alliances are all necessary to keep a competitive edge in the market.

For instance, in July 2022, to bring Apollo's specialized high performing NGS tests, such as hereditary cancer genetic screenings (GCC) and pharmacogenetics screenings (PGx), to the wider clinical market, 1health.io Inc. ("1health"), an industry-leading software company, partners with Apollo Health Group. 1health empowers diagnostic laboratories to expand their testing in both the clinical and the direct-to-consumer markets rapidly and securely.

On November 29, 2022, The University of Pecs (UP) and BGI Genomics decided to open a collaborative lab in Hungary. This is a provision of the cooperation agreement between the University and BGI Group, the parent organization of BGI Genomics.

Expensive cost is expected to hamper the market's growth.

The laboratory equipment needs routine maintenance, which costs a lot of money and is one of the factors limiting market expansion.

COVID-19 Impact Analysis

COVID-19 has also had a detrimental impact on the market. For instance, the global use of lockdowns to follow social segregation to contain COVID-19 after the WHO labeled it a pandemic has negatively impacted the DNA testing market. Genetic counselors are generally unable to meet with patients one-on-one, doctors are often unavailable for counseling, and laboratories cannot do the necessary tests, which is the cause of this. Genetic counselors are not considered healthcare professionals by organizations like the Centres for Medical Services. Therefore they are not exempt from practicing during a lockdown. Additionally, clinics limited in-person genetic counseling to aid in the disease's containment.

However, companies that offer genetic testing, like GeneDx, offer a choice where they give the genetic tests as required by the clinician. Similar to how hospitals and other healthcare facilities use telehealth to offer genetic counseling, clinics are starting to do the same. Additionally, because of its importance, parental testing continues to be the least impacted method of DNA testing.

Consequently, COVID-19 has greatly impacted the market for genetic testing. However, the demand for genetic tests has currently approached pre-pandemic levels globally, and it is anticipated that this need will continue to increase.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The application segment is the highest market holder in the global DNA Testing market. Genetic testing uses medical tests to check for specific gene variants (changes). Several different genetic tests are being used today, and more are being created. There are numerous applications for genetic testing, but this article will concentrate on how it is used to find gene mutations connected to cancer. Predictive genetic testing is used to look for inherited gene alterations that may increase a person's chance of developing particular types of cancer. People with a history of cancer or a particular pattern of cancer in their family may benefit from genetic counseling and testing.

During the projected period, the primary drivers of the cancer segment are the rising incidence of cancers worldwide and the rising public awareness of preventive diagnostics and individualized medication. The American Cancer Society predicted that in 2021 there would be roughly 1,898,160 new cancer cases and 608,570 cancer deaths in the country. The International Agency for Research on Cancer also predicted that by 2040, there would be 30.2 million additional cases of cancer (IARC). Consequently, it is anticipated that an increase in cancer incidence will considerably contribute to the segment's growth.

Genetic tests help determine whether cancer runs in the family and the risk factors for cancer development in the future for people with a family history of the disease. Additionally, genetic testing is done on individuals who do not react to chemotherapy to determine if tumors resistant to treatment have acquired mutations.

Geographical Analysis

Asia Pacific holds the largest market share in the global DNA testing market.

Asia Pacific dominates the global DNA testing market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to the rising frequency of chronic and genetic conditions in the region and the rising demand for individualized genetic testing services, Asia Pacific now dominates the global market for genetic testing. The market expansion in the Asia Pacific is predicted to be driven by the rising number of product approvals by governments and subsequent launches, as well as the high concentration of key players engaged in research activities to innovate novel genetic testing products.

In August 2022, the debut of GENEe- TO The GENE, THE CORRECT WAY, a cutting-edge idea for providing Genetic Counselling services to patients, has been eagerly anticipated by Redcliffe Labs. Additionally, customers can use the recently opened, cutting-edge Genetic Lab in India, the country's first of its type. Redcliffe Labs hopes to provide a complete solution ranging from routine pathology at the basic level to clinical and high-end research genomics with the opening of a specialist Genetics Lab.

In May 2020, A new step of their collaboration with Illumina was announced by the Chinese company Burning Rock, a leader in next-generation sequencing (NGS) oncology diagnosis. In accordance with the new contract, Burning Rock will be the first genetic testing business in China to create in vitro diagnostic (IVD) tests using tissue samples and circulating tumor DNA (ctDNA) on Illumina's NextSeq 550Dx Sequencing System. The cooperation expands on a 2015 partnership that enabled the use of the MiSeq Dx Sequencing System for several NGS-based cancer therapy selection solutions.

Competitive Landscape

The DNA testing market is moderately competitive with local and global companies' presence. Natera, Inc, Roche Diagnostics, Abbott Laboratories, Cephide Inc, Gen-probe Inc, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Hologic Inc, Siemens Healthier and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in October 2022, Medline announced its multi-year vendor partnership with Hoag Memorial Hospital Presbyterian health system to provide essential medical supplies portfolio to the acute and non-acute care network.

Natera, Inc.

Overview: Cell-free DNA (cfDNA) testing pioneer Natera is committed to oncology, women's health, and organ health. In order to safeguard health and enable earlier and more precise actions that result in longer, healthier lives, the goal is to integrate customized genetic testing and diagnostics into the accepted standard of care.

Product Portfolio:

Panorama: Panorama is a blood-based genetic, prenatal screening test of the pregnant person that screens for common chromosomal conditions that affect a baby's health. Panorama uses SNP-based technology to deliver highly accurate results and unique insights for both singleton and twin pregnancies.

The global DNA testing market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The development of new tests and technological breakthroughs
      • 4.1.1.2. Demand for direct-to-consumer DNA testing is expanding.
    • 4.1.2. Restraints:
      • 4.1.2.1. Expensive cost is expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Reagents
  • 7.4. Software & Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. PCR
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. In situ hybridization
  • 8.4. Sequencing Technology
  • 8.5. Mass Spectrometry
  • 8.6. Others

9. By Applications

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 9.1.2. Market Attractiveness Index, By Applications
  • 9.2. Oncology
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious disease testing
  • 9.4. Myogenic disorder diagnosis
  • 9.5. Clinical diagnosis confirmation
  • 9.6. Prenatal diagnosis
  • 9.7. Pre-implantation diagnosis
  • 9.8. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Point of Care
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Self Testing/OTC

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByApplication
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Italy
      • 11.3.8.5. Spain
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. Australia
      • 11.5.8.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Natera, Inc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Roche Diagnostics
  • 13.3. Abbott Laboratories
  • 13.4. Cephide Inc
  • 13.5. Gen-probe Inc
  • 13.6. Illumina, Inc.
  • 13.7. Thermo Fisher Scientific
  • 13.8. Bio-Rad Laboratories
  • 13.9. Hologic Inc
  • 13.10. Siemens Healthier.

LIST NOT EXHAUSTIVE

14. Global DNA Testing Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us